StockData

Alvotech vs MeiraGTx

ALVO and MGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and MGTX compare

MeiraGTx grew revenue faster over the last twelve months (948% versus 19.7% for Alvotech).

MeiraGTx scores higher on the StockData Score (13 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOMGTX
Size and price
Market cap–$839M
Share price$4.41$8.74
Change, 1 year−20.2%5.8%
Change, 5 years−55.5%−51.3%
Beta (5Y)0.362.09
Employees1,000403
StockData Score
Total score313 (better)
Valuation score04 (better)
Growth score22
Performance score04 (better)
Health score13 (better)
Dividend score00
Valuation
P/E–12.3×
P/S–2.1×
EV/EBITDA–4.1×
P/FCF–80.2×
FCF yield–1.2%
Fair value–$24.59
Margin of safety–64.5%
Growth
Revenue growth (TTM)19.7%948% (better)
Revenue growth, 5Y average54.5% (better)39.2%
Profitability
Gross margin59.8%–
Operating margin13.3%46.3% (better)
Net margin–19.9%
FCF margin−19.6%2.6% (better)
Return on equity–2668%
Return on invested capital–344%
Financial health
Net debt / EBITDA10.02 (better)−0.22
Interest coverage0.5×14.7× (better)
Current ratio1.653.76 (better)
Altman Z-score–3.33
Piotroski F-score–4
Dividends and buybacks
Buyback yield–−15.9%
Shareholder yield–−15.9%
Ownership
Held by institutions–82.5%
Held by insiders67.7%35.2%
Insider net buying, 12 months–−$4.7M
Short interest, % of float–10.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.